ONC

#400
BeOne Medicines Ltd. American Depositary Shares
311.6100 USD
+1.95%
Sector:
Básica: USD
Divisa de beneficio: USD
Rango diario
305.8800
313.3500
Rango anual
271.4701
385.2200
Cambio diario
+1.95%
Variación mensual
+8.91%
Variación en los últimos 6 meses
-1.30%
Cambio anual
-1.30%
Cierres anteriores
305.6400
Abrir
305.8800
Bid
Ask
Mínimo
305.8800
High
313.3500
Volumen
141
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
Informe de resultados Saldo Flujo de caja
Valor 202020212022202320242025 TTM

BeOne Medicines Ltd - American Depositary Shares

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025.